📇 Rhumatologue · PARIS · (75) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Référence presse grand public
Cité 3 fois dans les médias — pédagogie reconnue
Disponibilité géographique
4 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
2
2 articles ont été cités au moins 2fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Total citations reçues
11
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
5
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
0
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital américain de paris
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
CLINIQUE ARAGO
GHP SAINT JOSEPH - BATIMENT A 187 R RAYMOND LOSSERAND, 75014 PARIS
CENTRE EXCELLENCE IMAGERIE
20 B AV MAC MAHON, 75017 PARIS
IRM PARIS HOCHE
192 BD HAUSSMANN, 75008 PARIS
INSTITUT DE RADIOLOGIE DE PARIS
31 AVENUE HOCHE, 75008 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Whatsupdoc-lemag.fr · 15/07/2025
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxONjVBckI2TEFMOVFETlc3QnVSYmtaMVpkZHZ5MmZ1bURzOVpDTFl3NTIwak84Ti1xMW14X0NCcVh1WGd0SkptX2EtMEF6TjEzeWxMUXVOWWsxelJGaWU1Yko0aGxGUHdOWUVQeVRyWTA3aThuQmhVaF9jTloxMHZwV2lGR1ZSNHh4QjFNWnBqVl84WEpFdzJ4NE5UcVhOeVd6cV9GMG1iWmxsaHhSWHFDZ25HOA?oc=5" t
📰 Docteur Imago · 25/07/2024
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNT0hmWU5FVkh3SU0yR3lYVy10NDRMYzRhRDhfMkRIRDBTeDU1RXF2aGpkQVNSRUxESGgtV2poNDk0UEYwTDFGeW5LUjZGR2l0LTAzVnhKOS1pcVc2NFNsMDFWbkpJUDFVVzNxeDBDWUhPWXpvdHJHVGhfSXZGcWI3ZTRhMW1ZR1ExNlFRT1Q5ZFhSRzRhMnZKVnBPS0FUQnJjTE8ybUhfSUZiSmI2NzhDNDlLNkUtaHJGaV
📰 Le Parisien · 25/10/2018
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdXZwdlNRTEx1UE1mZHBBbldtaVRXRkxJbGY2OXlvbXhRcElUODFmODEyaG0xMXlOTUpfb1lOX0NLaXFBTE9od1BlQkdXcHc5dWdZZTMxdGh2dVA3eXVmUUJpNkRuVHZMRTJNT0FyekxjXzdWcldxNE4tdkdGUWZVa2F0cEkxU0FtZjJVVkZLemQ4YVBXRFJybFpPZ1BFZDIxVXRVdW16QmRZcDVUNkg0RFVUVEJuc0hJYk
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
Abstract Background Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. Methods In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up. The primary endpoint was confirmed cytomegalovirus clearance at end of week 8. The key secondary endpoint was achievement of cytomegalovirus clearance and symptom control at end of week 8, maintained through week 16. Results 352 patients were randomized (235 maribavir; 117 IAT). Significantly more patients in the maribavir versus IAT group achieved the primary endpoint (55.7% vs 23.9%; adjusted difference [95% confidence interval (CI)]: 32.8% [22.80–42.74]; P &lt; .001) and key secondary endpoint (18.7% vs 10.3%; adjusted difference [95% CI]: 9.5% [2.02–16.88]; P = .01). Rates of treatment-emergent adverse events (TEAEs) were similar between groups (maribavir, 97.4%; IAT, 91.4%). Maribavir was associated with less acute kidney injury versus foscarnet (8.5% vs 21.3%) and neutropenia versus valganciclovir/ganciclovir (9.4% vs 33.9%). Fewer patients discontinued treatment due to TEAEs with maribavir (13.2%) than IAT (31.9%). One patient per group had fatal treatment-related TEAEs. Conclusions Maribavir was superior to IAT for cytomegalovirus viremia clearance and viremia clearance plus symptom control maintained post-therapy in transplant recipients with R/R cytomegalovirus. Maribavir had fewer treatment discontinuations due to TEAEs than IAT. Clinical Trials Registration. NCT02931539 (SOLSTICE).
Transplant infectious disease : an official journal of the Transplantation Society · 2022
AbstractThe CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV‐specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV. image
Journal of cutaneous pathology · 2010
We report a rare case of multiple, co‐exisitng verruciform xanthomas (VXs) of the anogenital region in the setting of cutaneous trauma. VX is a rare benign mucocutaneous neoplasm that typically presents as a solitary lesion with a predilection for the oral cavity, although extra‐oral lesions have been reported involving the vulva, scrotum, penis, anal region and extremities. The etiology and pathogenesis of VX have yet to be determined; however, recent literature has reported that multifocal cutaneous VX are frequently associated with pre‐existing inflammatory processes. A significant number of VXs of the skin have been found to co‐exist with cutaneous disorders including graft vs. host disease, discoid lupus erythematosus, pemphigus vulgaris, and recessive dystrophic epidermolysis bullosa. Therefore, we speculate severe cutaneous trauma and chronic inflammation may induce epithelial keratinocytes to respond aberrantly leading to epidermal hyperplasia and foamy cell formation characterizing the VX lesion.Cumberland L, Dana A, Resh B, Fitzpatrick J, Goldenberg G. Verruciform xanthoma in the setting of cutaneous trauma and chronic inflammation: report of a patient and a brief review of the literature.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Transplant infectious disease : an official journal of the Transplantation Society · 2022 · Journal Article
Kotton CN, Torre-Cisneros J, International CMV Symposium Faculty, Aguado JM, et al.
Case reports in dermatological medicine · 2017 · Case Reports
Salna MP, Singer HM, Dana AN
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022 · Clinical Trial, Phase III
Avery RK, Alain S, Alexander BD, Blumberg EA, et al.
Journal of cutaneous pathology · 2010 · Case Reports
Cumberland L, Dana A, Resh B, Fitzpatrick J, et al.